Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes

BACKGROUND: A significant improvement in clinical signs was demonstrated with abrocitinib relative to placebo in adolescents with moderate‐to‐severe atopic dermatitis (AD) in three phase 3, randomized, double‐blinded, placebo‐controlled studies (JADE TEEN [ClinicalTrials.gov, NCT03796676], JADE MONO...

Descripción completa

Detalles Bibliográficos
Autores principales: Cork, M.J., McMichael, A., Teng, J., Valdez, H., Rojo, R., Chan, G., Zhang, F., Myers, D.E., DiBonaventura, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Allergy and Eczema
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299698/
https://www.ncbi.nlm.nih.gov/pubmed/34743361
http://dx.doi.org/10.1111/jdv.17792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299698/
https://www.ncbi.nlm.nih.gov/pubmed/34743361
http://dx.doi.org/10.1111/jdv.17792

Ejemplares similares